Increasing Research Supported by Progressing R&D and Diagnostic Technologies to Amplify Tumour-Induced Osteomalacia Market Demand: States Fact.MR

Tumour-induced osteomalacia or oncogenic osteomalacia is a rare paraneoplastic syndrome of bone which consist of osteomalacia or rickets induced by phosphaturic mesenchymal tumour (PMT). Tumour-induced osteomalacia diagnosed with an elevated level of blood fibroblast growth factor 23 (FGF23), phosphate and vitamin D-regulating hormone. According to Maastricht University Hospital research, paraneoplastic syndrome affects 8% of cancer patients.

Request for Sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=5255

Tumour-Induced Osteomalacia Market Segmentation

The global tumour-induced osteomalacia market is segmented into treatment, diagnosis, end-user and regions.

By treatment, the global tumour-induced osteomalacia market is further segmented into:

• Drugs
  • Burosumab-twza
  • Cinarcalcet
• Supplements
  • Calcium (Cinarcalcet,
  • Vitamin D (Calcitriol or Alphacalcidio)
  • Phosphorus
• Surgery

By diagnosis, the global tumour-induced osteomalacia market is further segmented into:

• Laboratories
  • Elevated blood Fibroblast growth factor 23 (FGF-23)
  • Serum calcium, PTH, vitamin D
  • Hyperphosphaturia (Secondary effects of the FDF-23)
  • Hypophosphatemia (Secondary effects of the FDF-23)
• Bone Scan
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT Scan)

• Differential Diagnosis
  • Vitamin D metabolism and deficiency
  • Osteoporosis
  • Renal Osteodystrophy
  • Others

By end-user, the global tumour-induced osteomalacia market is further segmented into:

• Hospitals
• Clinics

Tumour Induced Osteomalacia Market: Drivers and Restraints

The global tumour-induced osteomalacia market is driven by the escalating R&D, close collaboration of research institutes, recent successful clinical trials, drug approvals and pipeline drugs. The governments have dedicated funds for orphan drug research and rare diseases which also pushes the tumour-induced osteomalacia market growth. Research bodies and manufacturers are working with the deliberated focus to develop novel diagnostics and therapeutics for tumour-induced osteomalacia. Drugs such as recently FDA approved tumour-induced osteomalacia drug, Burosumab and fast track designated by FDA, BGJ398 is expected to drive the tumour-induced osteomalacia market growth prospects.

However, several restraints decelerate the tumour-induced osteomalacia such as the high expenses of research which eventually adds cost to the diagnostics and treatment. The treatment of tumour-induced osteomalacia possess challenges such as lack of awareness, the dearth of knowledge among clinical professionals and patients since the disease is rare and only 500 cases reports since the first case reported in 1947, therefore limited data in the literature, restricted patient and clinical data. Tumour-induced osteomalacia drugs require repeated dosage and adverse reactions. Although, the overall tumour-induced osteomalacia market is expected to grow lucratively with a gradual pace with the advancing research and dedicated databases for rare diseases and increasing understanding of the disease pathophysiology.

Request Customized Report as Per Your Requirements – https://www.factmr.com/connectus/sample?flag=RC&rep_id=5255

Tumour Induced Osteomalacia Market: Key Players

The key players of global tumour-induced osteomalacia market include Kyowa Kirin Co., Ltd., Taizhou Hisound Pharmaceutical Co., Ltd., Zhejiang Garden Biochemical High-tech Co., Ltd., Kingdomway Nutrition, Inc., Amgen Inc., Forgo Pharmaceuticals Pvt. Ltd., Abbott, Solvay, GE Healthcare, Siemens and others.

Tumour Induced Osteomalacia Market: Regional Outlook

The global tumour-induced osteomalacia market is expected to grow gradually further with the advancing research, drug approvals and clinical trials. By treatment, the segment of surgery is anticipated to lead the tumour-induced osteomalacia treatment, since surgeries are considered safer than the drugs for their adverse reactions, repeated dosages of drugs, effective tumour destructions, controlling the serum phosphate level and pain relief.

By diagnosis, the bone scans are anticipated to dominate the segment with their sophisticated technology and high expenditure. By end-user, hospitals are expected to rule the segment with their highly advanced infrastructure and expenditure, diagnostics, patient care for tumour-induced osteomalacia and highly experienced medical professionals.

North America is anticipated to lead the global tumour-induced osteomalacia market with its highly advanced research infrastructure, diagnostics and treatment, close collaborations between research institutes and hospitals, dedicated funds and programs for rare disease research and orphan drugs development. Europe is anticipated holds the second-largest tumour-induced osteomalacia market with its sophisticated R&D and diagnostics technology and escalated investments into the research.

Asia-Pacific tumour-induced osteomalacia market is anticipated to grow eventually with the progressing research infrastructure and investments of nations such as China and India. Latin America tumour-induced osteomalacia market is expected to have a very gradual growth with its awareness programs. The Middle East and Africa tumour-induced osteomalacia market are anticipated to be stagnant due to the underdeveloped research and healthcare infrastructure and lack of awareness.

Enquire Before Buying Here – https://www.factmr.com/connectus/sample?flag=EB&rep_id=5255

The Report Covers Exhaustive Analysis On:

• Tumour-Induced Osteomalacia Market Drivers, Segments and Restraints.
• Tumour-Induced Osteomalacia Market Survey and Dynamics
• Tumour-Induced Osteomalacia Market Size & Demand
• Tumour-Induced Osteomalacia Key Trends/Issues/Challenges
• Tumour-Induced Osteomalacia Sales, Competition & Companies involved

Read More Trending Reports of Fact.MR- https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/ 

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

About Us:

Fact.MR research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: sales@factmr.com

Visit Our Website: https://www.factmr.com

The post Increasing Research Supported by Progressing R&D and Diagnostic Technologies to Amplify Tumour-Induced Osteomalacia Market Demand: States Fact.MR appeared first on Latest Market Reports.